Clinical Trials Directory

Trials / Completed

CompletedNCT00896662

Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202

Status
Completed
Phase
Study type
Observational
Enrollment
9 (actual)
Sponsor
Vanderbilt-Ingram Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying the dendritic cells in samples of blood from patients with cancer receiving aflibercept may help doctors learn about the effect of aflibercept on dendritic cells. PURPOSE: This laboratory study is evaluating dendritic cells in patients with advanced solid tumors or non-Hodgkin lymphoma receiving aflibercept on clinical trial VGFT-ST-0202.

Detailed description

OBJECTIVES: * Evaluate the effect of in vivo aflibercept on the presence of different populations of dendritic cells (DC) and immature cells (ImC) in the peripheral blood of cancer patients by characterizing the time course (kinetics) of the improvement in antigen presenting cell (APC) phenotype (decline in DC/ImC ratio) occurring early and late after aflibercept administration. * Evaluate the effect of aflibercept administration on DC function based on ability to stimulate antigen specific proliferative (allogeneic and tetanus toxoid) and cytolytic T cell responses (influenza) by characterizing the time course (kinetics) of the improvement in APC function occurring early and late after aflibercept administration. * Explore the relationship of baseline aflibercept level and host APC phenotype. OUTLINE: This is a multicenter study. Patients undergo phlebotomy and blood collection at baseline and on days 15, 29, and 57. Samples are analyzed for dendritic cell phenotype, subpopulations, maturation status, and function in terms of ability to activate autologous T cells.

Conditions

Interventions

TypeNameDescription
OTHERimmunologic techniqueimmunologic technique
OTHERlaboratory biomarker analysislaboratory biomarker analysis
OTHERpharmacological studypharmacological study

Timeline

Start date
2005-01-01
Primary completion
2007-10-01
Completion
2008-08-01
First posted
2009-05-12
Last updated
2016-04-25

Source: ClinicalTrials.gov record NCT00896662. Inclusion in this directory is not an endorsement.